Current Management of Non-Alcoholic Fatty Liver Disease (NAFLD)

Benny Budiman(1),


(1) Department of Internal Medicine, Mitra Medika Hospital, Pontianak
Corresponding Author

Abstract


Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of other causes of liver fat accumulation. The prevalence of NAFLD is increasing and now among top causes of hepatocellular carcinoma. The diagnosis of NAFLD requires evidence from liver biopsy. There are currently no specific drugs for therapy of NAFLD. Current mainstay for management of NAFLD is lifestyle interventions focused around weight loss. Lifestyle interventions can be done by dietary modification or increasing physical activity level. Pioglitazone and vitamin E are only recommended for patient whom was confirmed NAFLD by liver biopsy. New agents such as obeticholic acid, elafibranor, selonsertib, and cenicriviroc are still waiting for phase III result to be recommended as therapy for NAFLD. Bariatric surgery can be advised for NAFLD patient with obesity who is not adequately controlled by medical therapy.


Keywords


fatty liver; management; lifestyle; drugs

Full Text: PDF

Article Metrics

Abstract View : 115 times
PDF Download : 67 times

DOI: 10.24871/251202463-70

Refbacks

  • There are currently no refbacks.